Bepirovirsen liver biopsy study for hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests a new drug called bepirovirsen for people with chronic hepatitis B. It aims to see if the drug works by checking liver tissue samples before and after treatment. Be aware it involves a liver biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years or older.
- You have had hepatitis B for at least 6 months.
- You are either on a stable dose of hepatitis B medication (no changes for 6 months) or not on any hepatitis B treatment.
- Your hepatitis B surface antigen level must be 1000 IU/ml or lower.
- Your liver enzyme (ALT) level must be within 2 times the normal upper limit.
- You must be willing to have a liver biopsy as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This trial tests an experimental drug called AHB-171 for people with chronic hepatitis B. It aims to see if the drug is safe and how well it works. You may be able to join if you have had hepatitis B for at least 6 months and meet other health requirements.
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Hear when a new HEPATITIS B CHRONIC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.